Vonoprazan Fumarate
FDA-approved product (tablet, oral), marketed as Voquezna.
- Registered studies
- 24
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Gastroesophageal reflux disease
- Peptic ulcer
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Proton pump inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli30.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis55.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
24registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Vonoprazan Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Helicobacter Pylori Rescue Treatment in Patients Allergic to Penicillin
NCT05135182 · start 2021-11-28
Registered record
- Registry ID
- NCT05135182
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Furazolidone; Metronidazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2021-11-28
- Completion
- 2022-12
- Enrolment
- 170
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter Pylori InfectionInterventionFurazolidone; MetronidazolePhasePhase 4Registry statusUnknownHelicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin
NCT05129176 · start 2021-11-23
Registered record
- Registry ID
- NCT05129176
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Levofloxacin; Metronidazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2021-11-23
- Completion
- 2022-11
- Enrolment
- 106
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter Pylori InfectionInterventionLevofloxacin; MetronidazolePhasePhase 4Registry statusUnknownBismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
NCT05049902 · start 2021-09-21
Registered record
- Registry ID
- NCT05049902
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Amoxicillin; Clarithromycin; Tetracycline; Metronidazole; Bismuth Potassium Citrate; Colloidal Bismuth Pectin; Vonoprazan fumarate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2021-09-21
- Completion
- 2023-06-30
- Enrolment
- 1,300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter Pylori InfectionInterventionAmoxicillin; Clarithromycin; Tetracycline; Metronidazole +3 morePhasePhase 4Registry statusCompletedEfficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection
NCT04991584 · start 2021-08-04
Registered record
- Registry ID
- NCT04991584
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2021-08-04
- Completion
- 2022-07-01
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter Pylori InfectionInterventionAmoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,PhaseNot applicableRegistry statusUnknownThe Impact of WeChat Group Patient Education on the Eradication Rate of Helicobacter Pylori
NCT04850209 · start 2021-07-23
Registered record
- Registry ID
- NCT04850209
- Conditions
- Helicobacter Pylori Infection; Helicobacter Pylori Eradication; Patient Education
- Interventions
- oral and written education; Wechat group
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2021-07-23
- Completion
- 2022-09-10
- Enrolment
- 438
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter Pylori Infection; Helicobacter Pylori Eradication; Patient EducationInterventionoral and written education; Wechat groupPhaseNot applicableRegistry statusCompletedDifferences in the Eradication of Helicobacter Pylori by Different Therapies
NCT05097846 · start 2021-06-17
Registered record
- Registry ID
- NCT05097846
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Group1 Vonoprazan Fumarate + amoxicillin + doxycycline; Group2 Vonoprazan Fumarate + furazolidone + doxycycline; Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline; Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2021-06-17
- Completion
- 2022-10-17
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter Pylori InfectionInterventionGroup1 Vonoprazan Fumarate + amoxicillin + doxycycline; Group2 Vonoprazan Fumarate + furazolidone + doxycycline; Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline; Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycyclinePhaseNot applicableRegistry statusUnknownBismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days
NCT04901117 · start 2021-06
Registered record
- Registry ID
- NCT04901117
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Amoxicillin; Clarithromycin; Tetracycline; Metronidazole; Bismuth Potassium Citrate; Colloidal Bismuth Pectin; Vonoprazan fumarate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2021-06
- Completion
- 2023-08
- Enrolment
- 1,300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter Pylori InfectionInterventionAmoxicillin; Clarithromycin; Tetracycline; Metronidazole +3 morePhasePhase 4Registry statusUnknownThe Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
NCT04810793 · start 2020-07-01
Registered record
- Registry ID
- NCT04810793
- Conditions
- Helicobacter Pylori
- Interventions
- Amoxicillin , Levofloxacin and Esomeprazole; Amoxicillin , Furazolidone and Esomeprazole; Tetracycline , Furazolidone and Esomeprazole; Amoxicillin,Levofloxacin and Vonoprazan fumarate; Amoxicillin,Furazolidone and Vonoprazan fumarate; Tetracycline,Furazolidone and Vonoprazan fumarate
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2020-07-01
- Completion
- 2022-06-30
- Enrolment
- 820
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHelicobacter PyloriInterventionAmoxicillin , Levofloxacin and Esomeprazole; Amoxicillin , Furazolidone and Esomeprazole; Tetracycline , Furazolidone and Esomeprazole; Amoxicillin,Levofloxacin and Vonoprazan fumarate +2 morePhaseNot recordedRegistry statusCompletedVonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety
NCT02679508 · start 2016-03-20
Registered record
- Registry ID
- NCT02679508
- Conditions
- Erosive Esophagitis
- Interventions
- Vonoprazan; Lansoprazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2016-03-20
- Completion
- 2022-03-05
- Enrolment
- 208
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErosive EsophagitisInterventionVonoprazan; LansoprazolePhasePhase 4Registry statusCompleted